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ABSTRACT 1 
Transvenous lead extraction (TLE) of the Starfix coronary sinus (CS) active-fixation lead may 2 
be challenging, due to undeployment of fixation lobes and venous occlusion. We report our 3 
experience in Starfix TLE, in comparison with previous data.   4 
A 78-year-old male, implanted in 2009 with Starfix lead, was referred to our institution for 5 
TLE, due to infective endocarditis with lead-associated vegetations. The tip of Starfix lead 6 
was located in distant, anterior position, in the Great Cardiac Vein, close to patent LIMA-to-7 
LAD anastomosis, and first-choice surgical removal had a prohibitive operative risk.  8 
Conventional dilatation beyond CS os, as well as the use of a standard delivery catheter, was 9 
ineffective. An off-label modification of the delivery, by cutting the distal soft tip, was 10 
successful. However, the tip of the lead fragmented and was trapped in the innominate vein. 11 
Then a gooseneck snare grasped the fragment, allowing complete retrieval.  12 
TLE of Starfix leads may be particularly challenging, especially when its tip is located in a 13 
distant anterior location. In these cases, important help may be obtained by dilatation within 14 
the CS, by means of conventional or modified delivery catheters. Only experienced operators, 15 
sometimes with non-conventional techniques, should perform TLE of Starfix leads.  16 
Abstract word count: 197 17 18 
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 1 
LEARNING OBJECTIVE 2 
TLE of Starfix leads may be challenging, particularly when the tip is located in a distant 3 
anterior position. Dilatation with conventional tools may be precluded. In these cases 4 
modifications of the delivery catheters may be useful. Surgery should be avoided as first-5 
choice procedure; only experienced operators, sometimes with non-conventional techniques, 6 
should perform TLE of Starfix leads. 7 
Learning objective word count: 56 8 
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 1 
INTRODUCTION 2 
Implantation of left ventricular (LV) leads through coronary sinus (CS) may be challenging. 3 
Dislodgements of LV leads accounts for 41-10% of cases,2-5 with threshold worsening, loss of 4 
capture, phrenic nerve stimulation and inadequate cardiac resynchronization therapy (CRT). 5 
Technology improvements, like preformed shapes of LV leads, were developed to maintain 6 
adequate stability. Even more, active fixation leads were introduced (Attain Starfix OTW LV 7 
Lead, Model 4195, Medtronic, Minneapolis, MN, USA). First experience with such leads was 8 
reported in 2007,6 with only 0.7% dislodgement rates at two-year follow-up,7 and improved 9 
success rate of CRT.8 However, the difficulty of using such LV active fixation leads was 10 
confirmed, particularly with respect to transvenous lead extraction (TLE),9 even in recently 11 
implanted leads.6, 7  12 
 13 
CASE REPORT 14 
A 78-year-old male patient was referred to our institution for TLE, due to pocket infection 15 
with lead-associated vegetations.  16 
Clinical history. 17 
In 1991 the patient suffered an inferior myocardial infarction, and the same year he underwent 18 
surgical revascularization with left internal mammary artery (LIMA) anastomisation to left 19 
anterior descending (LAD). In 2009, due to depressed ejection fraction with inducible 20 
ventricular tachycardia at electrophysiological study, the patient was implanted at another 21 
centre with a single chamber ICD; a double coil passive fixation shock lead was used (Sprint 22 
Quattro, Model 6944, Medtronic Inc., Minneapolis, MN, USA). From January 2011 the 23 
patient experienced relapsing skin dehiscence at the generator pocket, with exposure of the 24 
can and lead. The absence of systemic involvement was accepted, by the referring physicians 25 
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and in contrast to Expert Consensus,10 as warranting repeated two local repair procedures, 1 
with deep relocation of the exposed lead and pulse generator, and one generator replacement 2 
with preservation of the lead. Even so, due to worsened heart failure with left bundle branch 3 
block, the device was upgraded to a biventricular system in November 2011. Permanent low-4 
rate atrial fibrillation led to implantation of a new LV lead only. Lateral and postero-lateral 5 
CS branches were not suitable for implantation, and stability issues resulted in the choice of 6 
an active fixation lead (Attain Starfix LV OTW Lead, Model 4195, Medtronic Inc.), which 7 
was anteriorly located in the mid-portion of the great cardiac vein (GCV). A biventricular 8 
device (Concerto II CRTD D 294 TRK, Medtronic) was implanted, with the atrial port 9 
capped. The procedure was complicated by pocket hematoma, requiring surgical revision one 10 
month later. On June 2014, new skin erosion was evident, with further exposure of one lead. 11 
A transoesophageal echocardiography disclosed lead-associated filiform images, along the 12 
transatrial segment of both right ventricular shock and LV CS lead, finally and clearly 13 
convincing the colleagues of the need of TLE. 14 
Patient evaluation and diagnostic work-up. 15 
After admission to our centre, control coronary angiography showed proximal occlusion of 16 
the LAD, Circumflex and Right coronary arteries, with myocardial perfusion due completely 17 
to a patent LIMA-to-LAD anastomosis. Myocardial perfusion with 99Tcm-18 
methoxyisobutylisonitrile (MIBI) stress/rest SPECT disclosed a wide irreversible inferior and 19 
infero-lateral defect, and a small partially reversible apical defect. Therefore, the only viable 20 
myocardial tissue was that located in the anterior position, perfused through the above-21 
mentioned LIMA-to-LAD graft.  22 
Cardiac surgeons ruled out surgical lead extraction as first-choice procedure, due to expected 23 
difficulty and risk of removing a lead implanted in close proximity with a working LIMA-to-24 
LAD anastomosis (Figure 1, Panel A; Video 1). 25 
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Transvenous lead extraction. 1 
TLE was performed under local anaesthesia in the Electrophysiology Lab, with a cardiac 2 
surgery team on active duty and with support of an Anaesthesiologist and with working 3 
anaesthesia equipment in the room. We used manual traction with conventional and locking 4 
stylets, and dilation with polypropylene sheaths (Cook Vascular Inc., Leechburg, PA, USA). 5 
The size of the sheaths, all provided with bevelled ends, ranged from 7 to 11.5 French. We 6 
used the single-sheath technique described by Bongiorni,11 and counter-traction. 7 
First, the Sprint Quattro lead was extracted with conventional polypropylene Byrd mechanical 8 
dilators (Cook Vascular Inc.), up to the 11.5-French inner XL “white” one (Figure 1, Panel B; 9 
Video 2). A subsequent selective retrograde CS venography disclosed an occlusion at the mid 10 
portion of the main CS (Figure 1, Panels C and D). A 0.014” Hi-Torque Balance 11 
Middleweight guide (Abbott Vascular, Santa Clara, CA, USA), inserted through the Swan-12 
Ganz lumen, was able to gain access to the distal CS (Figure 1, Panels E and F; Video 3). The 13 
LV led was cut as usual, and a long standard CS stylet (Model 6054, 0.016”, 110 cm, 14 
Medtronic) was inserted and secured with ties. Advancing the push tubing of the Starfix along 15 
the lead body resulted in a partial undeployment of the proximal lobes only. A manual 16 
traction attempt was ineffective; therefore, dilatation was performed along the LV lead using 17 
the inner 7.0-French and 8.5-French XL Byrd dilators, with the bevel stopping immediately 18 
after CS entrance (Figure 1, Panel G; Video 4).  A 57-cm long 7-French CS delivery (Attain 19 
Command CS Cannulation Catheter, Model 6250VI-57S, Medtronic) was advanced over the 20 
LV lead near the origin of the GCV (figure 1, Panels H and I; and Figure 2, Panels A to D; 21 
Video 5). Then, as previously described,12 the soft tip collar of the delivery was cut, in order 22 
to produce a greater pushing force along the lead. This off-label modified delivery was able to 23 
reach the proximal series of the fixation lobes, resulting in their further undeployment (Figure 24 
2, Panels E to H; Video 6). The distal end of this modified delivery was firmly anchored to 25 
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the proximal lobes, allowing repeated traction to be effective in extracting the lead from the 1 
CS (Figure 2, Panel I; Video 7). The tip of the Starfix lead, with its distal fixation lobes 2 
deployed, not protected inside a dilator, was trapped in the proximal innominate vein, 3 
immediately before the costo-clavicular angle narrowing (Figure 3, Panel A). Manual traction 4 
resulted in fragmentation of the lead, with its tip retained, and consequent occlusion of the 5 
vein (figure 3, Panel B). A Lassos snare catheter, 90° loop angle, 30 mm loop diameter 6 
(OSYPKA AG, D-79618 Rheinfelden-Herten, Germany) was unsuccessful in catching the 7 
lead fragment (Figure 3, Panel C). A 0.025” J Tip PTFE guide wire (Medtronic Inc.), driven 8 
by a 7-French MPA 1 guiding catheter (Cordis Corp., Miami Lakes, FL, USA), could pass 9 
through the occlusion, and the lead tip was partially freed (Figure 3, Panel D). An Amplatz 10 
Goose Neck 6-French snare catheter, with a 30mm loop snare (ev3 Inc., Plymouth, MN, 11 
USA), was then used to grasp the tip (Figure 3, Panels E to G), thereby allowing complete 12 
retrieval of the tip fragment through a 18-french long femoral sheath (Cook Vascular)(Figure 13 
3, Panels H and G; Video 8). Subsequent course was uneventful. Particularly, no pericardial 14 
effusion was observed.  15 
 16 
DISCUSSION 17 
The extraction of the Attain Starfix lead clearly can be particularly challenging, even with 18 
recently implanted leads (within 4 weeks).6  Previous experiences of Starfix TLE are reported 19 
in Table 1, with regard to dwelling time, implant site, undeployment of fixation lobes, 20 
technique used and progression of sheaths within the main CS, beyond CS entrance, or its 21 
branches. Only cases with intention-to-treat indication to TLE were considered, while 22 
repositioning and implant revisions were not taken into account. Moreover, TLE was defined 23 
according to HRS Expert Consensus.10 Dwelling time of extracted Starfix leads was 24 
599,1±271.1 days (range 69 to 1029).  The Starfix tip, as referred by the Authors or as could 25 
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have been gathered from the analysis of the published images, was located in a posterolateral, 1 
lateral or anterolateral position. The bevel of the dilators could reach the main CS in 15 out of 2 
19 patients, where information could be have been gained, and a CS branch only in 7. 3 
Undeployment of fixation lobes was frequently prevented, 7, 13-16 often occurring only with 4 
proximal ones.12-14 Such a mechanism may be responsible for acute failures in extracting 5 
leads, while chronically venous occlusion, due to reduction and slowing of blood flow with 6 
consequent thrombosis,17 may collaborate with worsening effect. Success rate for Starfix TLE 7 
is approximately 73%, clearly below the 96-98% reported rate for intracardiac conventional18 8 
and passive fixation CS leads.19 9 
Our described case confirms some key points about TLE of the Starfix lead: the 10 
undeployment of fixation lobes, the venous occlusion (in our case affecting the main middle 11 
CS, not just the collateral venous branches), the impossibility of conventional mechanical 12 
dilatation just beyond CS entrance, and the effectiveness of dilatation within the CS by means 13 
of conventional and/or modified CS delivery catheters.  14 
To the best of our knowledge, with respect to published data, some features of this case are 15 
unique and should be highlighted.  16 
The dwelling time of the Starfix lead was 988 days, well beyond the majority of extracted 17 
case (only one cases of the Cleveland population was implanted as long as 1029 days).13 Our 18 
patient is the only one in which the Starfix lead was located in an anterior position, in the mid 19 
portion of the GCV. Such a distant location increases the difficulty of reaching the distal tip 20 
and performing dilatation along the lead. The progression of sheaths is even more difficult, 21 
due to the wide and almost complete curve along the main CS, and the narrow distal 22 
angulation of the vein where it reaches the interventricular groove.  23 
Our case is the first one in which the tip of the Starfix lead is located in close proximity to a 24 
patent coronary artery anastomosis. Our surgeons refused elective surgical removal of the tip, 25 
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because of its risky location, of the redo procedure, with presumably tough dissection of old 1 
adherences surrounding the heart, and of high surgical risk of the patient. In other cases, 2 
failure of transvenous extraction of the Starfix lead was treated by urgent surgical 3 
intervention.15 In our patient, a surgical emergency procedure would have been prohibitive. 4 
Conclusions. 5 
Starfix lead extraction may be challenging due to the impossibility of undeployment of 6 
fixation lobes, with increasing difficulty for the frequently observed venous occlusion around 7 
the fixation mechanism. However, some important help may be obtained by dilatation within 8 
the CS, by means of conventional or modified delivery catheters. This approach must always 9 
be attempted, even in presumably difficult cases, due to the long dwelling time, unfavourable 10 
and distant anatomic location, and prohibitive surgical risk.  11  12 
 13 
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FIGURE LEGENDS 1 
 2 
Figure 1.   3 
Panel A: coronary angiography, showing a patent LIMA-to-LAD anastomosis in the 4 
interventricular grove, in close proximity to the tip of the Starfix lead. Circumflex and right 5 
coronary arteries are occluded, with myocardial perfusion entirely depending on this working 6 
anastomosis. Panel B: ICD shock lead extraction, with standard polypropylene Byrd dilators. 7 
Panel C and D: selective retrograde CS venography. The mid portion of the main CS, just 8 
beyond the inflated Swan-Ganz catheter balloon, is occluded. Panel E and F: a 0.014” Hi-9 
Torque BMW guide, inserted through the Swan-Ganz lumen, gains access to distal CS.  10 
Panel G: advancing the push tubing of the Starfix along the lead body results in a partial 11 
undeployment of the proximal lobes only. Therefore, dilatation along the LV lead is needed, 12 
using the inner 7.0-French XL Byrd dilator, with the bevel stopping immediately after CS 13 
entrance. Mechanical dilatation cannot progress just beyond CS os. Panel H and I: a 57-cm 14 
long 7-French CS delivery (Attain Command CS Cannulation Catheter, Model 6250VI-57S, 15 
Medtronic) is advanced over the LV lead into the mid portion off the main CS.   16 
 17 
Figure 2 18 
Panel A to C: further progression of the delivery into the CS. Panel D: the distal portion of 19 
the main CS is reached, just before the origin of the GCV in the interventricular grove. 20 
Panel E: off-label modification of the delivery, by cutting the soft distal collar of the catheter. 21 
The modification produces a greater pushing force along the lead, so reaching the origin of 22 
the GCV. Panel F to H: the distal end of this modified delivery is firmly anchored to the 23 
proximal lobes. Panel I: extraction.   24 
 25 
 26 
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Figure 3 1 
Panel A: during extraction, the tip of the Starfix, not protected inside a dilator, is trapped into 2 
the innominate vein, just before the costo-clavicular angle narrowing. Panel B: manual 3 
traction results in fragmentation of the lead, with its tip retained. Due to the traction forces 4 
carried out, the fixation lobes are forced against the vessel wall, and again fully deployed, so 5 
causing venous occlusion. Panel C: a Lassos snare catheter, 90° loop angle, 30 mm loop 6 
diameter is unsuccessful in catching the lead fragment.  Panel D: a 0.025” J Tip PTFE guide 7 
wire (Medtronic Inc.), driven by a 7-French MPA 1 guiding catheter (Cordis Corp., Miami 8 
Lakes, FL, USA), can pass through the occlusion, so allowing a selective venography, 9 
confirming the occlusion. As a consequence of these manoeuvres, the lead tip is partially 10 
freed. Panel E and F: an Amplatz Goose Neck 6-French snare catheter, with a 30mm loop 11 
snare (ev3 Inc., Plymouth, MN, USA) catches the tip of the Starfix lead. Panel G: the traction 12 
over the tip undeploys the lobes, as can be see at the mid innominate vein level. Panel H and 13 
I: the tip fragment of the Starfix lead is extracted through a long 18-French femoral sheath. 14 
 15 
 16 
